Core Viewpoint - Recently, Regeneron Biotech announced the launch of its personalized mRNA tumor vaccine (code RH125) clinical research project, which aims to evaluate the safety, tolerability, and therapeutic effects of the vaccine alone or in combination with PD-1 inhibitors in patients with advanced solid tumors [1] Group 1: Clinical Research Details - The study is an investigator-initiated exploratory clinical trial (IIT) co-initiated by Academician Xu Binghe and Director Chang Jianhua, who defined the clinical research protocol [1] - The trial focuses on assessing the personalized mRNA vaccine based on tumor neoantigens, addressing the limited treatment options and poor prognosis faced by advanced solid tumor patients [1] Group 2: Technological Advancements - Regeneron Biotech possesses leading artificial intelligence neoantigen prediction algorithms, mRNA nucleic acid delivery systems, and immune enhancement technologies [1] - The launch of RH125 in the IIT study is expected to provide new treatment options for patients with advanced solid tumors, potentially improving their quality of life [1]